Thetis adds $1.4M Helmsley loan, lifting its gut-repair IBD program to $15.4M
What's the deal? Thetis Pharmaceuticals has secured an additional $1.4 million from The Leona M. and Harry B. Helmsley Charitable Trust to advance TP-317, its oral drug candidate for inflammatory bowel disease (IBD). The money arrives as a program-related investment loan, a debt instrument the foundation uses to back mission-aligned therapies.
What's the company building? The clinical-stage firm is developing TP-317, a first-in-class oral BLT1 agonist designed to do more than dampen inflammation. It targets epithelial repair and fibrosis reduction — the tissue damage that drives disease progression in Crohn's disease and ulcerative colitis.
By the numbers: The new loan brings Thetis's total Helmsley funding to $15.4 million, including $8.975 million earmarked for a Phase 1b trial of TP-317 in patients with moderate-to-severe ulcerative colitis.
Where the money goes: Part of the loan funds preclinical studies to validate TP-317's signaling pathways in human intestinal epithelial cells and to inform exploratory biomarkers of repair. The Phase 1b is a 12-week, randomised, double-blind, placebo-controlled study measuring safety, pharmacokinetics, and an efficacy signal.
Why it matters: Current IBD treatments leave only a minority of patients in lasting remission. Thetis positions TP-317 as a non-immunosuppressive combination partner meant to add mucosal healing on top of existing therapies rather than replace them.
"Helmsley's continued support allows us to evaluate TP-317 in patients with ulcerative colitis, with endpoints that capture epithelial repair and fibrosis in addition to clinical response," said Gary Mathias, co-founder and chief executive officer of Thetis.
The foundation framed its backing around disease-modifying potential. "That's why we support Thetis with TP-317, a novel, promising drug candidate with the potential to alter IBD disease course and lead to intestinal healing," said Jessica Langer, program officer at Helmsley.
The signal: Mission-driven foundations are increasingly using patient debt rather than equity to push early biotech through costly trials — a model that lets specialist funders like Helmsley keep backing a single candidate across multiple milestones.
Read more: thetispharma.com
Image credit: Generated with Gemini